Amgen develops and manufactures biotechnology medicines for serious diseases, including oncology, cardiovascular conditions, bone health, inflammation, and rare diseases. Its marketed therapies include biologics, small molecules, and products acquired through its Horizon Therapeutics transaction. The company combines drug discovery and clinical development with global biologics manufacturing and commercial distribution.
Amgen Inc. (AMGN) has a MarketKingdoms composite score of 71.9 (B+), an B-range rating. It ranks 177th of 1,866 covered companies, 6th of 78 in Healthcare (sector average 64.4) and 1st of 13 in Drug Manufacturers - General. Scores as of 2026-10-26.
Its strongest lenses are KPI momentum at 99 (Healthcare average 78) and Stock selection at 90 (Healthcare average 79). Its weakest lenses are Price (valuation) at 42 (sector average 50) and Expansion (growth) at 44 (sector average 50).
| Lens | Type | AMGN | Healthcare average | Drug Manufacturers - General average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 81 | 81 | 81 | 65th |
| Stock selection | Research signal | 90 | 79 | 78 | 100th |
| KPI momentum | Research signal | 99 | 78 | 77 | 100th |
| Catalyst watch | Research signal | 75 | 74 | 71 | 56th |
| Price (valuation) | Fundamental lens | 42 | 50 | 53 | 36th |
| Expansion (growth) | Fundamental lens | 44 | 50 | 39 | 44th |
| Quality (profitability) | Fundamental lens | 66 | 50 | 60 | 72nd |
| Trend (momentum) | Fundamental lens | 76 | 50 | 55 | 86th |
The most recent call analysed was held on 2026-08-04 (fiscal 2026 Q2). After it the composite moved from 85.1 to 84.4. MarketKingdoms checks what management promised on each call against what it later delivered.
The composite at the time of each event; today's composite is 71.9.
The stock's valuation gap is +13.9%: its price is above the path its market, sector and industry moves explain (overvalued versus the model path). Factor sensitivity: market beta 1.68, sector beta 0.23, industry beta 1.12; the factor model explains 59% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| Eli Lilly & Co. (LLY) | 71.2 | B+ | +1.7% |
| AbbVie Inc. (ABBV) | 69.0 | B | -3.2% |
| Bristol-Myers Squibb Co. (BMY) | 66.3 | B | -11.0% |
| Biogen Inc. (BIIB) | 65.9 | B | +31.0% |
| Gilead Sciences Inc. (GILD) | 65.5 | B | -3.5% |
| GSK plc ADR (GSK) | 63.0 | B- | -5.1% |
| Novo Nordisk ADR (NVO) | 62.9 | B- | -24.0% |
| Novartis AG ADR (NVS) | 62.1 | B- | -3.9% |
Amgen Inc. financial statements · Healthcare sector ranking · Drug Manufacturers - General industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.